Syndax Pharmaceuticals Stock Tumbles on Failed IPF Trial

3-line summary

• Syndax Pharmaceuticals (Nasdaq: SNDX) said its Phase 2 MAXPIRe trial of axatilimab in idiopathic pulmonary fibrosis (IPF) failed to meet its primary endpoint of annualized decline in forced vital capacity (FVC), and the company will not pursue further development in the IPF indication.
• The trial enrolled 145 patients across 62 sites in 14 countries, randomized 2:1 to axatilimab 0.3 mg/kg or placebo every two weeks for 26 weeks. Safety was comparable to placebo with no new safety signals and no treatment-related deaths in either arm. Shares fell roughly 15% in after-hours trading Monday.
• Syndax said the result does not affect ongoing trials in other indications, including chronic graft-versus-host disease (cGVHD), where axatilimab is already FDA-approved; data from those trials are expected later this year and in early 2028.

This summary is our own processing of the source article; see the source link below for full context.